Delving into the Latest Updates on 3D011-08 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

PDGFR antagonists(Platelet-derived growth factor receptor antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

3D Medicines (Beijing) Co., Ltd.Startup

Active Organization

3D Medicines (Beijing) Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Dose escalation phase: evaluate the safety and tolerability of 3D011-08 monotherapy in subjects with advanced solid tumors. Dose expansion phase: evaluate the preliminary efficacy of 3D011-08 monotherapy in subjects with advanced hepatocellular carcinoma, advanced renal cell carcinoma, and metastatic castration-resistant prostate cancer.

Start Date-

Sponsor / Collaborator

3D Medicines (Beijing) Co., Ltd.Startup

NCT05099536 / WithdrawnPhase 1

A Phase I Study of the Safety, Tolerability, Pharmacokinetics Profiles and Preliminary Efficacy of 3D011-08 for Injection Monotherapy in Subjects With Advanced Solid Tumors

The purpose of this study is evaluate the the safety, tolerability, pharmacokinetics profiles, and preliminary efficacy of 3D011-08 in subjects with advanced solid tumors.

Start Date24 Feb 2022

Sponsor / Collaborator

3D Medicines (Beijing) Co., Ltd.Startup

100 Clinical Results associated with 3D011-08

Login to view more data

100 Translational Medicine associated with 3D011-08

Login to view more data

100 Patents (Medical) associated with 3D011-08

Login to view more data

100 Deals associated with 3D011-08

Login to view more data